iBio (IBIO) Competitors $0.81 +0.01 (+1.79%) Closing price 04:00 PM EasternExtended Trading$0.81 0.00 (-0.49%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBIO vs. MGX, OSTX, SLGL, UNCY, CVM, VNRX, ABVC, ELYM, ANL, and QNTMShould you be buying iBio stock or one of its competitors? The main competitors of iBio include Metagenomi (MGX), OS Therapies (OSTX), Sol-Gel Technologies (SLGL), Unicycive Therapeutics (UNCY), CEL-SCI (CVM), VolitionRx (VNRX), ABVC BioPharma (ABVC), Eliem Therapeutics (ELYM), Adlai Nortye (ANL), and Quantum Biopharma (QNTM). These companies are all part of the "pharmaceutical products" industry. iBio vs. Its Competitors Metagenomi OS Therapies Sol-Gel Technologies Unicycive Therapeutics CEL-SCI VolitionRx ABVC BioPharma Eliem Therapeutics Adlai Nortye Quantum Biopharma Metagenomi (NASDAQ:MGX) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership. Do institutionals and insiders hold more shares of MGX or IBIO? 7.9% of iBio shares are owned by institutional investors. 17.8% of Metagenomi shares are owned by company insiders. Comparatively, 0.6% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend MGX or IBIO? Metagenomi presently has a consensus target price of $10.00, suggesting a potential upside of 336.68%. iBio has a consensus target price of $5.00, suggesting a potential upside of 516.52%. Given iBio's higher probable upside, analysts plainly believe iBio is more favorable than Metagenomi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00iBio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, MGX or IBIO? iBio has lower revenue, but higher earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$52.29M1.64-$78.06M-$2.36-0.97iBio$400K39.85-$24.91M-$1.74-0.47 Is MGX or IBIO more profitable? iBio has a net margin of 0.00% compared to Metagenomi's net margin of -257.99%. Metagenomi's return on equity of -37.84% beat iBio's return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-257.99% -37.84% -27.15% iBio N/A -73.15%-45.51% Which has more risk & volatility, MGX or IBIO? Metagenomi has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500. Comparatively, iBio has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Does the media favor MGX or IBIO? In the previous week, Metagenomi and Metagenomi both had 2 articles in the media. Metagenomi's average media sentiment score of 0.95 beat iBio's score of 0.00 indicating that Metagenomi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryiBio beats Metagenomi on 8 of the 14 factors compared between the two stocks. Get iBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetriciBioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$15.94M$860.40M$5.64B$21.46BDividend YieldN/A4.84%5.79%3.55%P/E Ratio-0.471.1875.7529.49Price / Sales39.8526.21557.1660.52Price / CashN/A17.6437.1124.34Price / Book0.586.4612.414.57Net Income-$24.91M-$5.42M$3.29B$1.00B7 Day Performance-5.61%-0.26%1.26%-0.20%1 Month Performance3.04%5.21%3.84%2.42%1 Year Performance-58.41%25.78%61.01%13.12% iBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOiBio1.2319 of 5 stars$0.81+1.8%$5.00+516.5%-57.2%$15.94M$400K-0.47100Gap DownMGXMetagenomi2.7648 of 5 stars$1.82-2.2%$10.00+449.5%+10.0%$69.81M$52.29M-0.77236News CoverageOSTXOS Therapies1.6635 of 5 stars$2.20-2.2%$18.00+718.2%-29.4%$69.62MN/A-2.78N/AGap UpSLGLSol-Gel Technologies0.6968 of 5 stars$23.96-3.4%N/A+298.6%$69.11M$11.54M-19.4850Gap DownUNCYUnicycive Therapeutics2.4267 of 5 stars$3.94+1.8%$57.00+1,346.7%-11.2%$68.35M$680K-0.969CVMCEL-SCI0.7286 of 5 stars$9.87-3.7%N/A-73.0%$67.93MN/A-20.5643Positive NewsVNRXVolitionRx1.5365 of 5 stars$0.63-3.9%$3.50+455.4%-2.7%$67.81M$1.32M-1.7580ABVCABVC BioPharma0.6765 of 5 stars$2.87+0.7%N/A+367.3%$67.09M$510K-16.8830ELYMEliem TherapeuticsN/A$2.25-6.3%N/A-59.1%$66.94MN/A-4.259ANLAdlai Nortye1.9504 of 5 stars$1.77-1.1%$9.00+409.9%-17.6%$65.87M$5M0.00127Positive NewsGap DownQNTMQuantum Biopharma0.3695 of 5 stars$17.40+1.0%N/A+349.2%$65.75MN/A-1.24N/A Related Companies and Tools Related Companies MGX Alternatives OSTX Alternatives SLGL Alternatives UNCY Alternatives CVM Alternatives VNRX Alternatives ABVC Alternatives ELYM Alternatives ANL Alternatives QNTM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IBIO) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IBIO Stock Alerts